Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PHAT Phathom Pharmaceuticals

Market Closed 06-26 16:00:00 EDT

10.72

+0.38

+3.68%

盘后10.51

-0.21-1.96%

19:48 EDT

High10.78	Low10.11	Vol2.66M
Open10.43	D1 Closing10.34	Amplitude6.43%
Mkt Cap851.49M	Tradable Cap617.12M	Total Shares79.43M
T/O28.13M	T/O Rate4.62%	Tradable Shares57.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PHAT","market":"US","secType":"STK","nameCN":"Phathom Pharmaceuticals","latestPrice":10.72,"timestamp":1782504000000,"preClose":10.34,"halted":0,"volume":2661554,"hourTrading":{"tag":"盘后","latestPrice":10.51,"preClose":10.72,"latestTime":"19:48 EDT","volume":238624,"amount":2557958.33348,"timestamp":1782517716786,"change":-0.21,"changeRate":-0.01959,"amplitude":0.01959},"delay":0,"changeRate":0.036750483558994275,"floatShares":57566899,"shares":79430117,"eps":-2.085468,"marketStatus":"Market Closed","change":0.38,"latestTime":"06-26 16:00:00 EDT","open":10.43,"high":10.775,"low":10.11,"amount":28129014.051222,"amplitude":0.064313,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.085468,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782720000000},"marketStatusCode":7,"adr":0,"listingDate":1571976000000,"exchange":"NASDAQ","adjPreClose":10.34,"preHourTrading":{"tag":"盘前","latestPrice":10.43,"preClose":10.34,"latestTime":"09:29 EDT","volume":101,"amount":1053.300013,"timestamp":1782480556086,"change":0.09,"changeRate":0.008704,"amplitude":0.004836},"postHourTrading":{"tag":"盘后","latestPrice":10.51,"preClose":10.72,"latestTime":"19:48 EDT","volume":238624,"amount":2557958.33348,"timestamp":1782517716786,"change":-0.21,"changeRate":-0.01959,"amplitude":0.01959},"volumeRatio":3.0522275253616136,"impliedVol":0.3168,"impliedVolPercentile":0.0359},"requestUrl":"/m/hq/s/PHAT/wiki","defaultTab":"wiki","newsList":[{"id":"2646846919","title":"Analysts Conflicted on These Healthcare Names: Phathom Pharmaceuticals (PHAT) and Elicio Therapeutics (ELTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646846919","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646846919?lang=en_us&edition=fundamental","pubTime":"2026-06-25 04:40","pubTimestamp":1782333620,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Phathom Pharmaceuticals (PHAT) and Elicio Therapeutics (ELTX). Ph...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-phathom-pharmaceuticals-phat-and-elicio-therapeutics-eltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-phathom-pharmaceuticals-phat-and-elicio-therapeutics-eltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELTX","BK4139","BK4007","BK4581","LU0128526141.USD","XBI","BK4588","BK4585","HCSG","XLV","PHAT","BK4137","LU0029874061.USD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645392418","title":"Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2645392418","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645392418?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:51","pubTimestamp":1782219090,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (PHAT) announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating Voquezna tablets as a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/phathom-pharmaceuticals-completes-enrollment-in-phalcon-eoe-201-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/phathom-pharmaceuticals-completes-enrollment-in-phalcon-eoe-201-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645369738","title":"Phathom Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of Voquezna","url":"https://stock-news.laohu8.com/highlight/detail?id=2645369738","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645369738?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:26","pubTimestamp":1782217604,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals  said Tuesday it has completed the enrollment in its phase 2 clinical trial evaluating Voquezna, or vonoprazan, as a potential treatment for eosinophilic esophagitis, a chronic inflammatory disease of the esophagus.The study enrolled 95 adult patients across 41 US clinical sites and is assessing the drug as a non-steroidal oral therapy. Topline results are expected in Q4, the company said.Phathom said the trial could help determine whether its acid suppression therapy offers a new treatment approach for patients who currently rely on proton pump inhibitors, which are not approved for the condition.If the results are positive, the company said it plans to engage with US regulators on further development, including potential pediatric studies and broader indications.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PHAT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645835120","title":"Phathom completes enrollment in Phase 2 VOQUEZNA trial for eosinophilic esophagitis in adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2645835120","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645835120?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:59","pubTimestamp":1782215960,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals completed enrollment in its Phase 2 pHalcon-EoE-201 trial of VOQUEZNA  in adult eosinophilic esophagitis.Topline results for the 12-week double-blind portion are expected in Q4 2026; results have not been presented yet.The placebo-controlled study is designed to assess whether vonoprazan can improve swallowing-related symptoms and disease activity versus placebo.A positive readout could support talks with the FDA on next development steps in EoE, including potential pediatric evaluation.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL8slZgR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00BN0W2W23.USD","BK4588","BK4007","PHAT","IE00B3QW5Z07.USD","SG9999014013.SGD","LU2210149790.SGD","BK4112","SG9999014005.SGD","LU0314104364.USD","LU2095319765.USD","SG9999014039.USD","LU2210150020.SGD","IE00BGHQF748.EUR","BK4585","IE00BN0W2V16.EUR","SG9999014021.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645835992","title":"Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 Phalcon-Eoe-201 Study of Voquezna® (Vonoprazan) in Eosinophilic Esophagitis (Eoe)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645835992","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645835992?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:59","pubTimestamp":1782215940,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA2YQXL3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHAT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645835918","title":"Phathom Pharmaceuticals - Topline Results From Phase 2 Trial Expected in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2645835918","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645835918?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:59","pubTimestamp":1782215940,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA2YQXL3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHAT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645836848","title":"Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645836848","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645836848?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:59","pubTimestamp":1782215940,"startTime":"0","endTime":"0","summary":"This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoETopline results for the double-blind 12-week treatment portion of the study are expected in Q4 o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/23/3315866/0/en/Phathom-Pharmaceuticals-Completes-Patient-Enrollment-Ahead-of-Schedule-in-Phase-2-pHalcon-EoE-201-Study-of-VOQUEZNA-vonoprazan-in-Eosinophilic-Esophagitis-EoE.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4124","PPI","TEN","BK4570","BK4007","BK4144","PHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644743765","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2644743765","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644743765?lang=en_us&edition=fundamental","pubTime":"2026-06-17 19:40","pubTimestamp":1781696441,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Phathom Pharmaceuticals (PHAT), Oncology Institute (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-231?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-231?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAT","TOI","BK4185","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644710478","title":"Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2644710478","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644710478?lang=en_us&edition=fundamental","pubTime":"2026-06-17 18:33","pubTimestamp":1781692380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHAT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 17, 2026 06:33 ET (10:33 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638542484","title":"Needham pharmaceuticals analysts hold analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2638542484","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638542484?lang=en_us&edition=fundamental","pubTime":"2026-05-27 03:00","pubTimestamp":1779822009,"startTime":"0","endTime":"0","summary":"Pharmaceuticals Analysts discuss Phathom Pharmaceuticals’s (PHAT) Voquezna (vonoprazan) on an Analyst/Industry conference call to be held on May 27...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/needham-pharmaceuticals-analysts-hold-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/needham-pharmaceuticals-analysts-hold-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637190773","title":"Phathom Pharma to present at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2637190773","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637190773?lang=en_us&edition=fundamental","pubTime":"2026-05-22 20:02","pubTimestamp":1779451365,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals management is scheduled to attend investor conferences on May 28, June 3, June 9.Fireside chats are set for June 3 at 12:15 pm EDT, June 9 at 2:40 pm EDT.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL2y7gBK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","SG9999014039.USD","LU0314104364.USD","LU2095319765.USD","BK4112","BK4007","SG9999014021.USD","SG9999014013.SGD","LU2210149790.SGD","IE00B64PRP62.GBP","NDAQ","PHAT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637639311","title":"Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2637639311","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637639311?lang=en_us&edition=fundamental","pubTime":"2026-05-22 20:00","pubTimestamp":1779451200,"startTime":"0","endTime":"0","summary":"FLORHAM PARK, N.J., May  22, 2026  (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastroin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/22/3300093/0/en/Phathom-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637924351","title":"Phathom Pharmaceuticals shareholders elected Class I directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2637924351","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637924351?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:01","pubTimestamp":1779393714,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals held its annual shareholder meeting on May 19, 2026.Shareholders ratified Ernst & Young as the independent registered public accounting firm for fiscal 2026.Shareholders re-elected three directors to three-year terms running to the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phathom Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 21, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL7MHFF1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636570844","title":"Phathom presents Phase 3 pHalcon-NERD-301 vonoprazan symptom analysis at DDW 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2636570844","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636570844?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:02","pubTimestamp":1779278576,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals highlighted new clinical research on its acid blocker vonoprazan at Digestive Disease Week 2026, with results already presented during the May 2-5 meeting in Chicago.Company-sponsored analyses from its Phase 3 pHalcon-NERD-301 trial showed symptom improvement in non-erosive GERD patients treated with vonoprazan versus placebo, with one poster receiving a Poster of Distinction designation.Phathom also presented a Phase 1 lactation study designed to assess vonoprazan levels in breast milk, supporting potential labeling and prescribing discussions for use in nursing patients.Independent investigator abstracts at the meeting broadened the evidence base across erosive esophagitis, H. pylori treatment, and longer-term safety versus older acid-suppression drugs, reinforcing commercial positioning for VOQUEZNA across acid-related conditions.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL8K0QKg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT","LU2210149790.SGD","BK4585","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014021.USD","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014013.SGD","NDAQ","BK4588","SG9999014005.SGD","BK4007","BK4112","IE00BKPKM429.USD","IE00BN0W2V16.EUR","SG9999014039.USD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","LU2095319765.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636844068","title":"Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2636844068","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636844068?lang=en_us&edition=fundamental","pubTime":"2026-05-20 20:00","pubTimestamp":1779278400,"startTime":"0","endTime":"0","summary":"31 vonoprazan-related clinical abstracts presented at Digestive Disease Week (DDW) 2026, including 28 independent analyses across GI conditions and three Phathom-sponsored clinical research abstractsI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/20/3298395/0/en/Phathom-Pharmaceuticals-Highlights-Breadth-of-Independent-Vonoprazan-Research-at-Digestive-Disease-Week-2026-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NERD","PHAT","BK4007","BK4144","SOCL","PPI","BK4124","BK4570","TEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634492602","title":"Phathom (PHAT) Is Up 9.4% After Reaffirming 2026 Profitability Timeline And Narrowing Q1 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2634492602","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634492602?lang=en_us&edition=fundamental","pubTime":"2026-05-09 14:45","pubTimestamp":1778309114,"startTime":"0","endTime":"0","summary":"In late April 2026, Phathom Pharmaceuticals reported that its first-quarter net loss narrowed to US$30.37 million from US$94.32 million a year earlier, while maintaining full-year 2026 net revenue guidance of US$320 million to US$345 million and expecting operating profitability, excluding stock-based compensation, to begin in the third quarter of 2026.\nThe company also disclosed a change in how it classifies certain third-party costs starting January 1, 2026, which could make future margins...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phat/phathom-pharmaceuticals/news/phathom-phat-is-up-94-after-reaffirming-2026-profitability-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phat/phathom-pharmaceuticals/news/phathom-phat-is-up-94-after-reaffirming-2026-profitability-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","PHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632261481","title":"Phathom to highlight VOQUEZNA at DDW annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2632261481","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632261481?lang=en_us&edition=fundamental","pubTime":"2026-05-01 20:01","pubTimestamp":1777636884,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals will participate in Digestive Disease Week  2026, scheduled for May 2-5 in Chicago.VOQUEZNA  product theater presentation set for May 4 at 12:00 PM CDT.Company will exhibit at DDW 2026 at booth 2511.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL6jMmFq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BGHQF748.EUR","BK4112","LU2210149790.SGD","SG9999014013.SGD","LU0314104364.USD","NDAQ","IE00BN0W2W23.USD","IE00BKPKM429.USD","PHAT","SG9999014039.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","SG9999014021.USD","LU2095319765.USD","IE00B3QW5Z07.USD","BK4588","BK4585","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632061648","title":"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Phathom Pharmaceuticals (PHAT) and Zimmer Biomet Holdings (ZBH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632061648","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632061648?lang=en_us&edition=fundamental","pubTime":"2026-05-01 18:40","pubTimestamp":1777632011,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Phathom Pharmaceuticals (PHAT) and Z...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-phathom-pharmaceuticals-phat-and-zimmer-biomet-holdings-zbh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-phathom-pharmaceuticals-phat-and-zimmer-biomet-holdings-zbh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1267930573.SGD","LU2242652126.USD","XBI","LU0122379950.USD","IE0009355771.USD","IE00B4R5TH58.HKD","LU0128526141.USD","BK4137","LU0648001328.SGD","LU1057294990.SGD","LU0310799852.SGD","LU0708994859.HKD","IE00BJJMRZ35.SGD","LU0109394709.USD","LU0130102774.USD","BK4599","LU1267930813.SGD","ZBH","HCSG","BK4139","IE0002270589.USD","AMGN","BK4566","LU1267930490.SGD","BK4533","LU2242646821.SGD","PHAT","LU0211328371.USD","LU0792757196.USD","LU0029874061.USD","BK4581","LU2089984988.USD","LU1023059063.AUD","LABU","LU0320765992.SGD","LU0889565916.HKD","LU1571399168.USD","LU1201861249.SGD","BK4082","LU0130517989.USD","SG9999001440.SGD","LU0868494617.USD","LU1983299246.USD","LU0128525929.USD","LU0477156953.USD","BK4585","XLV","IE00BJT1NW94.SGD","LU0029864427.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632269502","title":"Phathom Pharmaceuticals Signals Strong Growth on Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2632269502","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632269502?lang=en_us&edition=fundamental","pubTime":"2026-05-01 09:11","pubTimestamp":1777597895,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals, Inc. (($PHAT)) has held its Q1 earnings call. Read on for the main highlights of the call. Phathom Pharmaceuticals’ latest...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/phathom-pharmaceuticals-signals-strong-growth-on-earnings-call?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/phathom-pharmaceuticals-signals-strong-growth-on-earnings-call?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631567635","title":"Phathom Pharmaceuticals Q1 Adj. EPS $(0.18) Beats $(0.32) Estimate, Sales $58.301M Beat $57.028M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2631567635","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631567635?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:01","pubTimestamp":1777546868,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.32) by 43.75 percent. This is a 83.18 percent increase over losses of $(1.07) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/04/52164050/phathom-pharmaceuticals-q1-adj-eps-0-18-beats-0-32-estimate-sales-58-301m-beat-57-028m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.phathompharma.com","stockEarnings":[{"period":"1week","weight":-0.0147},{"period":"1month","weight":-0.0019},{"period":"3month","weight":0.0132},{"period":"6month","weight":-0.3895},{"period":"1year","weight":0.1225},{"period":"ytd","weight":-0.3538}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.079508},{"month":2,"riseRate":0.571429,"avgChangeRate":0.0658},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.119249},{"month":4,"riseRate":0.571429,"avgChangeRate":0.046876},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.041373},{"month":6,"riseRate":0.714286,"avgChangeRate":0.228355},{"month":7,"riseRate":0.666667,"avgChangeRate":0.025067},{"month":8,"riseRate":0.666667,"avgChangeRate":0.15186},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.003613},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.040055},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.100392},{"month":12,"riseRate":0.714286,"avgChangeRate":0.070942}],"exchange":"NASDAQ","name":"Phathom Pharmaceuticals","nameEN":"Phathom Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Phathom Pharmaceuticals(PHAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Phathom Pharmaceuticals,PHAT,Phathom Pharmaceuticals股票,Phathom Pharmaceuticals股票老虎,Phathom Pharmaceuticals股票老虎国际,Phathom Pharmaceuticals行情,Phathom Pharmaceuticals股票行情,Phathom Pharmaceuticals股价,Phathom Pharmaceuticals股市,Phathom Pharmaceuticals股票价格,Phathom Pharmaceuticals股票交易,Phathom Pharmaceuticals股票购买,Phathom Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Phathom Pharmaceuticals(PHAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}